Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Informatics

Start-up Odyssey buys machine-learning firm Rahko

by Michael McCoy
January 13, 2022 | A version of this story appeared in Volume 100, Issue 2

 

Odyssey Therapeutics, which launched in December with $218 million in funding to develop small-molecule drugs for cancer and inflammatory diseases, has made its first acquisition. Boston-based Odyssey has bought Rahko, a 3-year-old company with a drug discovery technique that combines computational chemistry, machine learning, and quantum computing. Odyssey CEO Gary D. Glick says in a statement that the purchase “gives Odyssey the opportunity to pair artificial intelligence and physics-based methods with a team of master drug-hunters.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.